KRT14 and neoplasm: We observed a significant reduction in tumor-free survival for K14-Cre/+;p53fl/fl;Perpfl/+mice (median tumor-free survival, 230 days) compared with K14-Cre/+;p53fl/fl control mice (median tumor-free survival, 265 days; P = 0.0224; Figure 5B).